KR20040058201A - 치매전 상태에 사용되는 로수바스타틴 - Google Patents
치매전 상태에 사용되는 로수바스타틴 Download PDFInfo
- Publication number
- KR20040058201A KR20040058201A KR10-2004-7005585A KR20047005585A KR20040058201A KR 20040058201 A KR20040058201 A KR 20040058201A KR 20047005585 A KR20047005585 A KR 20047005585A KR 20040058201 A KR20040058201 A KR 20040058201A
- Authority
- KR
- South Korea
- Prior art keywords
- dementia
- rosuvastatin
- cognitive
- risk
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012289 Dementia Diseases 0.000 title claims abstract description 44
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 title claims abstract description 32
- 229960000672 rosuvastatin Drugs 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000004556 brain Anatomy 0.000 description 15
- 102000001851 Low Density Lipoprotein Receptor-Related Protein-1 Human genes 0.000 description 12
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 12
- 208000024827 Alzheimer disease Diseases 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 208000010877 cognitive disease Diseases 0.000 description 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 208000027061 mild cognitive impairment Diseases 0.000 description 6
- 201000006474 Brain Ischemia Diseases 0.000 description 5
- 206010008120 Cerebral ischaemia Diseases 0.000 description 5
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 5
- 102000008052 Nitric Oxide Synthase Type III Human genes 0.000 description 5
- 108010075520 Nitric Oxide Synthase Type III Proteins 0.000 description 5
- 201000004810 Vascular dementia Diseases 0.000 description 5
- 206010008118 cerebral infarction Diseases 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 229930182558 Sterol Natural products 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000001149 cognitive effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 150000003432 sterols Chemical class 0.000 description 4
- 235000003702 sterols Nutrition 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 3
- 208000028698 Cognitive impairment Diseases 0.000 description 3
- 102000004316 Oxidoreductases Human genes 0.000 description 3
- 108090000854 Oxidoreductases Proteins 0.000 description 3
- 230000007000 age related cognitive decline Effects 0.000 description 3
- 159000000007 calcium salts Chemical class 0.000 description 3
- 230000003920 cognitive function Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 208000037259 Amyloid Plaque Diseases 0.000 description 2
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 2
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 2
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101100075486 Caenorhabditis elegans lrp-1 gene Proteins 0.000 description 2
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 102000012412 Presenilin-1 Human genes 0.000 description 2
- 108010036933 Presenilin-1 Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- -1 for example Chemical class 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 101150084157 lrp-1 gene Proteins 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010855 neuropsychological testing Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 208000037820 vascular cognitive impairment Diseases 0.000 description 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108010060159 Apolipoprotein E4 Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- 101150013552 LDLR gene Proteins 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 description 1
- 239000005516 coenzyme A Substances 0.000 description 1
- 229940093530 coenzyme a Drugs 0.000 description 1
- 231100000876 cognitive deterioration Toxicity 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000037041 intracellular level Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- LALFOYNTGMUKGG-BGRFNVSISA-L rosuvastatin calcium Chemical compound [Ca+2].CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O.CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O LALFOYNTGMUKGG-BGRFNVSISA-L 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0103509A SE0103509D0 (sv) | 2001-10-19 | 2001-10-19 | Rosuvastatin in pre demented states |
| SE0103509-6 | 2001-10-19 | ||
| PCT/SE2002/001911 WO2003032995A1 (en) | 2001-10-19 | 2002-10-18 | Rosuvastatin in pre demented states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20040058201A true KR20040058201A (ko) | 2004-07-03 |
Family
ID=20285721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2004-7005585A Withdrawn KR20040058201A (ko) | 2001-10-19 | 2002-10-18 | 치매전 상태에 사용되는 로수바스타틴 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20060229321A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1446123A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005505605A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20040058201A (cg-RX-API-DMAC7.html) |
| CN (1) | CN1604780A (cg-RX-API-DMAC7.html) |
| AR (1) | AR036891A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR0213434A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2463597A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO5580773A2 (cg-RX-API-DMAC7.html) |
| HU (1) | HUP0401798A3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL161380A0 (cg-RX-API-DMAC7.html) |
| IS (1) | IS7218A (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA04003631A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20041840L (cg-RX-API-DMAC7.html) |
| PL (1) | PL369573A1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2004112422A (cg-RX-API-DMAC7.html) |
| SE (1) | SE0103509D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003032995A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200402844B (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537271A1 (en) | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of rosuvastatin calcium |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| US7777034B2 (en) | 2003-11-24 | 2010-08-17 | Teva Pharmaceutical Industries Ltd. | Crystalline ammonium salts of rosuvastatin |
| CN1894221B (zh) | 2003-12-02 | 2012-08-08 | 特瓦制药工业有限公司 | 用于表征罗苏伐他汀的参照标准品 |
| US7179916B2 (en) | 2004-07-13 | 2007-02-20 | Teva Pharmaceutical Industries Ltd. | Process for the preparation of rosuvastatin |
| CA2680693A1 (en) | 2005-02-22 | 2006-08-31 | Teva Pharmaceutical Industries Ltd. | Preparation of rosuvastatin |
| WO2007022488A2 (en) | 2005-08-16 | 2007-02-22 | Teva Pharmaceutical Industries Ltd. | Crystalline rosuvastatin intermediate |
| WO2012073256A1 (en) | 2010-11-29 | 2012-06-07 | Cadila Healthcare Limited | Salts of rosuvastatin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2648897B2 (ja) * | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
| US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
| AR022462A1 (es) * | 1999-02-06 | 2002-09-04 | Astrazeneca Uk Ltd | Uso de un agente que disminuye el colesterol |
| US20030100493A1 (en) * | 2001-07-19 | 2003-05-29 | Sol Weiss | Sublingual use of inhibitors in the biosynthesis of cholesterol |
-
2001
- 2001-10-19 SE SE0103509A patent/SE0103509D0/xx unknown
-
2002
- 2002-10-17 AR ARP020103895A patent/AR036891A1/es not_active Application Discontinuation
- 2002-10-18 US US10/492,971 patent/US20060229321A1/en not_active Abandoned
- 2002-10-18 CA CA002463597A patent/CA2463597A1/en not_active Abandoned
- 2002-10-18 IL IL16138002A patent/IL161380A0/xx unknown
- 2002-10-18 PL PL02369573A patent/PL369573A1/xx not_active Application Discontinuation
- 2002-10-18 JP JP2003535798A patent/JP2005505605A/ja active Pending
- 2002-10-18 KR KR10-2004-7005585A patent/KR20040058201A/ko not_active Withdrawn
- 2002-10-18 BR BR0213434-9A patent/BR0213434A/pt not_active Application Discontinuation
- 2002-10-18 HU HU0401798A patent/HUP0401798A3/hu unknown
- 2002-10-18 CN CNA028253477A patent/CN1604780A/zh active Pending
- 2002-10-18 MX MXPA04003631A patent/MXPA04003631A/es not_active Application Discontinuation
- 2002-10-18 EP EP02783893A patent/EP1446123A1/en not_active Withdrawn
- 2002-10-18 WO PCT/SE2002/001911 patent/WO2003032995A1/en not_active Ceased
- 2002-10-18 RU RU2004112422/14A patent/RU2004112422A/ru not_active Application Discontinuation
-
2004
- 2004-04-13 IS IS7218A patent/IS7218A/is unknown
- 2004-04-15 ZA ZA200402844A patent/ZA200402844B/en unknown
- 2004-04-19 CO CO04035705A patent/CO5580773A2/es not_active Application Discontinuation
- 2004-05-05 NO NO20041840A patent/NO20041840L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003032995A1 (en) | 2003-04-24 |
| PL369573A1 (en) | 2005-05-02 |
| CO5580773A2 (es) | 2005-11-30 |
| BR0213434A (pt) | 2004-11-09 |
| ZA200402844B (en) | 2005-01-24 |
| HUP0401798A3 (en) | 2005-06-28 |
| RU2004112422A (ru) | 2005-04-10 |
| US20060229321A1 (en) | 2006-10-12 |
| WO2003032995A8 (en) | 2004-06-03 |
| NO20041840L (no) | 2004-05-05 |
| AR036891A1 (es) | 2004-10-13 |
| EP1446123A1 (en) | 2004-08-18 |
| HUP0401798A2 (hu) | 2005-01-28 |
| MXPA04003631A (es) | 2004-07-30 |
| SE0103509D0 (sv) | 2001-10-19 |
| CN1604780A (zh) | 2005-04-06 |
| CA2463597A1 (en) | 2003-04-24 |
| IS7218A (is) | 2004-04-13 |
| JP2005505605A (ja) | 2005-02-24 |
| IL161380A0 (en) | 2004-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haustein et al. | Methotrexate in psoriasis: 26 years’ experience with low‐dose long‐term treatment | |
| ES2305118T3 (es) | Uso de rosuvastatina (zd-4522) en el tratamiento de hipercolesteremia familiar heterocigota. | |
| US6369103B1 (en) | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor | |
| US20130053414A1 (en) | Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate | |
| JP2001517617A (ja) | 神経変性疾患の治療を目的としてａｐｏｅレベルを増加させる方法 | |
| JP2002529500A (ja) | ＨＭＧＣｏＡレダクターゼ阻害剤を用いるアルツハイマー病の治療、予防および発症リスクの低下法 | |
| JP2011137023A (ja) | コレステロール低下薬の使用 | |
| KR20040058201A (ko) | 치매전 상태에 사용되는 로수바스타틴 | |
| AU2004275567B2 (en) | Therapeutic treatment | |
| RU2316341C2 (ru) | Применение атазанавира в терапии вич-инфекции | |
| MXPA06006831A (es) | Uso de estatinas para el tratamiento del sindrome metabolico. | |
| WO2019004465A1 (ja) | ペマフィブラートを含有する医薬 | |
| AU2002347698A1 (en) | Rosuvastatin in pre demented states | |
| AU2008201290B2 (en) | Therapeutic treatment | |
| WO2025006661A1 (en) | Therapeutic uses and doses of lp(a) disrupter compounds | |
| KR20070030182A (ko) | (+)-에리트로-메플로퀸의 약제학적 조성물 및 그것의 용도 | |
| Pacific et al. | Seizures associated with memantine use. | |
| JPWO2005026117A1 (ja) | 脳卒中再発抑制剤 | |
| WO2017146305A1 (ko) | 급성관동맥증후군에 동반되는 우울증 치료용 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20040416 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |